When one of the researchers on a study is the CEO of two companies that manufacture the supplement being tested, it’s especially important for stories to include some independent vetting of the results in their coverage. This story didn’t include that outside perspective.
We’re fans of The Washington Post’s “Quick Study” column and we’ve applauded it before. But we thought their coverage of an experimental Alzheimer’s disease treatment lacked crucial details. A competing Fox News story had many of the same shortcomings.